BOC-DL-脯氨酸乙酯 | 125347-83-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 脯氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: BOC-DL-脯氨酸乙酯
• 英文名称: Boc-DL-Proline ethyl ester
• 英文别名: 1-O-tert-butyl 2-O-ethyl pyrrolidine-1,2-dicarboxylate
• CAS: 125347-83-3
• 化学式: C₁₂H₂₁NO₄
• mdl: MFCD06656725
• 分子量: 243.3
• InChiKey: IBCLKOLOJLBQDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  305.6±35.0 °C(Predicted)
• 密度：
  1.100±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.833
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

文献信息

• [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLE SUBSTITUÉS À UTILISER EN TANT QU'INHIBITEURS DE SÉRINE PROTÉASE
  申请人：VERSEON CORP

  公开号：WO2016138532A1

  公开（公告）日：2016-09-01

  There are provided inter alia multisubstituted aromatic compounds useful for the inhibition of thrombin and/or kallikrein, which compounds include substituted pyrazolyl. There are additionally provided pharmaceutical compositions. There are additionally provided methods of treating and preventing certain diseases or disorders, which diseases or disorders are amenable to treatment or prevention by the inhibition of thrombin and/or kallikrein.

  提供了一些多取代芳香族化合物，其中包括取代吡唑基，用于抑制凝血酶和/或激肽释放酶。此外，还提供了药物组合物。此外，还提供了一种治疗和预防某些疾病或疾病的方法，这些疾病或疾病可以通过抑制凝血酶和/或激肽释放酶进行治疗或预防。
• SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP
  申请人：KARKI Rajeshri Ganesh

  公开号：US20120122764A1

  公开（公告）日：2012-05-17

  The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , B, X, m and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides pharmaceutical composition of compounds of the invention, and a combination of pharmacologically active agents and a compound of the invention.

  本发明提供了一种具有化学式I的化合物； 或其药学上可接受的盐，其中R 1 ，R 2 ，R 3 ，R 4 ，R 5 ，B，X，m和n在此处被定义。该发明还涉及制造该发明化合物的方法及其治疗用途。本发明进一步提供了该发明化合物的药物组合物，以及具有药理活性剂和该发明化合物的组合。
• [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS SPIROLACTAMES D'UN RÉCEPTEUR NMDA ET LEURS UTILISATIONS
  申请人：NAUREX INC

  公开号：WO2014120783A1

  公开（公告）日：2014-08-07

  Disclosed are compounds having enhanced potency in the modulation of NMD A receptor activity. Such compounds are contemplated for use in the treatment of conditions such as depression and related disorders. Orally available formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  揭示了在调节NMDA受体活性方面具有增强效力的化合物。这些化合物可用于治疗抑郁症和相关疾病。此外，还披露了口服制剂和其他药用可接受的化合物给药形式，包括静脉注射制剂。
• [EN] DIHYDROPYRAZOLOPYRIDINE COMPOUNDS<br/>[FR] COMPOSES DE DIHYDROPYRAZOLOPYRIDINE
  申请人：MITSUBISHI PHARMA CORP

  公开号：WO2004014910A1

  公开（公告）日：2004-02-19

  The present invention provides dihydropyrazolopyridine compounds represented by the formula (I):wherein each symbol is as defined in the specification, optically active forms thereof, and pharmaceutically acceptable salts thereof and hydrates thereof. The compounds of the present invention show a selective and strong inhibitory activity on glycogen synthase kinase-3 beta (GSK-3β), and are useful as medicaments for prevention and/or treatment of diabetes, diabetic complications and neurodegenerative diseases or as immunopotentiators.

  本发明提供了由式(I)表示的二氢吡唑吡啶化合物，其中每个符号如规范中定义，其光学活性形式，以及其药学上可接受的盐和水合物。本发明的化合物显示出对糖原合成酶激酶-3β（GSK-3β）的选择性和强烈的抑制活性，并可用作预防和/或治疗糖尿病、糖尿病并发症和神经退行性疾病或免疫增强剂的药物。
• Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof
  申请人：Iyer Pravin

  公开号：US20080146607A1

  公开（公告）日：2008-06-19

  Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R 1 , R 2 , R a and R b are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.

  该式化合物：或其药用可接受的盐，其中m、n、Ar、R1、R2、Ra和Rb在此处有定义。还提供了制药组合物、使用方法和制备该化合物的方法。